Bruker Co. (NASDAQ:BRKR) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Bruker Co. (NASDAQ:BRKR) have been assigned an average rating of “Moderate Buy” from the eleven brokerages that are presently covering the company, MarketBeat reports. Five investment analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $70.50.

A number of research firms recently issued reports on BRKR. Stifel Nicolaus lowered their target price on Bruker from $70.00 to $57.00 and set a “hold” rating on the stock in a research note on Friday, February 14th. The Goldman Sachs Group upgraded Bruker from a “sell” rating to a “neutral” rating and set a $60.00 price objective on the stock in a report on Thursday, December 5th. Guggenheim reiterated a “buy” rating on shares of Bruker in a research note on Monday, February 24th. Bank of America increased their price target on shares of Bruker from $78.00 to $80.00 and gave the stock a “buy” rating in a research note on Friday, December 13th. Finally, Barclays decreased their price objective on shares of Bruker from $69.00 to $65.00 and set an “overweight” rating for the company in a report on Monday, February 10th.

Institutional Investors Weigh In On Bruker

Hedge funds and other institutional investors have recently modified their holdings of the stock. True Wealth Design LLC boosted its holdings in Bruker by 4,636.4% in the 3rd quarter. True Wealth Design LLC now owns 521 shares of the medical research company’s stock valued at $36,000 after purchasing an additional 510 shares during the period. Eagle Bay Advisors LLC lifted its stake in shares of Bruker by 2,324.1% in the fourth quarter. Eagle Bay Advisors LLC now owns 703 shares of the medical research company’s stock valued at $41,000 after buying an additional 674 shares during the period. UMB Bank n.a. grew its position in Bruker by 37.5% during the fourth quarter. UMB Bank n.a. now owns 909 shares of the medical research company’s stock worth $53,000 after buying an additional 248 shares in the last quarter. GAMMA Investing LLC increased its stake in Bruker by 47.5% during the fourth quarter. GAMMA Investing LLC now owns 1,279 shares of the medical research company’s stock valued at $75,000 after acquiring an additional 412 shares during the period. Finally, Quadrant Capital Group LLC raised its holdings in Bruker by 18.2% in the 4th quarter. Quadrant Capital Group LLC now owns 1,273 shares of the medical research company’s stock valued at $75,000 after acquiring an additional 196 shares in the last quarter. Institutional investors and hedge funds own 79.52% of the company’s stock.

Bruker Trading Down 1.0 %

NASDAQ:BRKR opened at $46.68 on Thursday. The stock has a market cap of $7.08 billion, a PE ratio of 61.42, a price-to-earnings-growth ratio of 2.16 and a beta of 1.18. Bruker has a fifty-two week low of $44.11 and a fifty-two week high of $94.86. The company has a debt-to-equity ratio of 1.15, a current ratio of 1.60 and a quick ratio of 0.77. The stock’s 50-day moving average is $52.82 and its two-hundred day moving average is $58.00.

Bruker (NASDAQ:BRKR) last announced its quarterly earnings data on Thursday, February 13th. The medical research company reported $0.76 EPS for the quarter, beating analysts’ consensus estimates of $0.75 by $0.01. Bruker had a net margin of 3.36% and a return on equity of 21.01%. As a group, equities research analysts forecast that Bruker will post 2.69 earnings per share for the current fiscal year.

Bruker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 28th. Stockholders of record on Monday, March 17th will be issued a dividend of $0.05 per share. The ex-dividend date of this dividend is Monday, March 17th. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.43%. Bruker’s dividend payout ratio (DPR) is presently 26.32%.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.